Previous 10 | Next 10 |
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibi...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...
Grandsouth Bancorporation (GRRB) is expected to report for quarter end 2023-09-30 Cadence Bank (CADE) is expected to report $0.56 for Q3 2023 Enterprise Financial Services Corporation (EFSC) is expected to report $1.24 for Q3 2023 Blackhawk Bancorp Inc. (BHWB) is expected to report fo...
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Oct. 23, 2023 (GLOBE NEWSW...
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight. The c...
CrossFirst Bankshares Inc. (CFB) is expected to report $0.33 for Q3 2023 Charles Schwab Corporation (The) (SCHW) is expected to report $0.75 for Q3 2023 Sunwin Stevia International Inc (SUWN) is expected to report for quarter end 2023-07-31 Enerpac Tool Group Corp. (EPAC) is expected ...
Environmental Tectonics Corp. (ETCC) is expected to report for Q2 2024 Advaxis Inc. (ADXS) is expected to report for Q3 2023 Sunwin Stevia International Inc (SUWN) is expected to report for quarter end 2023-07-31 Passur Aerospace Inc (PSSR) is expected to report for quarter end 2023-0...
Odyssey Marine Exploration Inc. (OMEX) is expected to report for quarter end 2023-06-30 The Very Good Food Company Inc. (VGFCQ) is expected to report for quarter end 2023-06-30 SeaChange International Inc. (SEAC) is expected to report for Q1 2024 Allena Pharmaceuticals Inc. (ALNAQ) is...
QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 Amerityre Corp (AMTY) is expected to report for quarter end 2023-06-30 BYD Co - Class H (BYDDF) is expected to report for quarter end 2023-06-30 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q1 2024 Ea...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...